Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a primary focus towards orphan diseases. The company is a pioneer in the rapidly developing field of personalized cell-based therapies for solid tumors, and is using the proprietary ALECSAT platform to generate best-in-class therapeutics to treat cancers with a high unmet medical need.
Cytovac has a phase Ib investigator initiated exploratory trial ongoing in Triple Negative Breast Cancer (TNBC).
Cytovac have completed four phase I trials in glioblastoma multiforme, pancreatic cancer and prostate cancer.
The completed phase I trial in the aggressive brain cancer, glioblastoma multiforme, showed indications of prolonged survival. Glioblastoma has an average median survival of 15 months with today’s treatment.
The complete phase II data set in Glioblastoma (progression free survival as primary endpoint) will be published during 2021.
Other early phase I or II trials are being planned as stand alone or in partnership with other companies.
Cytovac has established an approved GMP manufacturing facility and research department which also support scientific development for other partners.
Cytovac has filed a patent for treating elder and severely ill COVID-19 patients with its ALECSAT platform technology.
The management team and board have extensive experience from development and commercialization of biotech products.